权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Regulation of lung cancer growth and metastasis by an actionable driver of vesicle biogenesis in the Golgi

高尔基体囊泡生物发生的可操作驱动因素对肺癌生长和转移的调节

基本信息

批准号：
10531617
负责人：
Jonathan M Kurie
金额：
$ 43.45万
依托单位：
UNIVERSITY OF TX MD ANDERSON CAN CTR
依托单位国家：
美国
项目类别：
财政年份：
2019
资助国家：
美国
起止时间：
2019-12-01 至 2024-11-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10531617
关键词：
1-Phosphatidylinositol 4-Kinase Acceleration Address Alleles Behavior Biogenesis Biological Blood Vessels CD8-Positive T-Lymphocytes CSF3 gene CXCL1 gene Cancer Model Cause of Death Cell Proliferation Cell Survival Cell physiology Cell secretion Cells Chromosomes Clinical Clinical Research Clinical Treatment Clinical Trials Coculture Techniques Dedications Development Disease Disseminated Malignant Neoplasm Docking Ectopic Expression Endothelial Cells Fibroblasts Fluorescence Foundations GOLPH3 gene Genetic Recombination Golgi Apparatus Granulocyte-Macrophage Colony-Stimulating Factor Growth IL8 gene Immunity Induction of Apoptosis Inflammation Inflammatory Interleukin-6 Invaded KRAS2 gene Lentivirus Link Lung Neoplasms Malignant - descriptor Malignant Neoplasms Malignant neoplasm of lung Measures Mediating Membrane Modeling Molecular Mus Myeloid Cells Neoplasm Metastasis Outcome Phosphoric Monoester Hydrolases Phosphotransferases Play Process Property Protein Secretion Proteins Regulation Rest Role STC2 gene Site Structure TIMP1 gene Testing Therapeutic Tissues Tumor Promotion Tumor Volume Vascular Endothelial Growth Factors Vesicle Work aerosolized angiogenesis antagonist behavior influence cancer cell clinical development cytokine effective therapy improved inhibitor inorganic phosphate insight lung cancer cell metastatic process mutant neoplastic cell novel therapeutic intervention novel therapeutics phosphatidylinositol 4-phosphate small hairpin RNA small molecule therapeutically effective trafficking trans-Golgi Network tumor tumor growth tumor microenvironment tumor progression tumorigenic

项目摘要

Few effective therapies are available for KRAS-mutant lung cancer (KMLC). To address this problem, we seek to elucidate the biological basis for KMLC growth and metastasis and to develop novel therapies on the basis of that improved understanding. Cancer cells secrete factors that promote tumor growth, matrix remodeling, angiogenesis, and inflammation, a process hereafter termed “malignant secretion”. Therapeutic strategies to block malignant secretion have not been developed. We have identified a chromosome 1q amplicon harboring and numerous regulators of vesicle biogenesis and trafficking, including phosphatidylinositol 4-kinase IIIβ (PI4KIIIβ), a Golgi-dedicated kinase that generates phosphatidylinositol 4-phosphate (PI4P). We show that the viability and proliferative and invasive activities of 1q–amplified KMLC cells require PI4KIIIβ. A selective PI4KIIIβ antagonist preferentially induced apoptosis and inhibited the metastatic properties of 1q–amplified KMLC cells. On the basis of these findings, we hypothesize that high PI4KIIIβ levels promote KMLC growth and metastasis and confer vulnerability to PI4KIIIβ antagonists. To test this hypothesis, we propose in Aim 1 to an autochthonous PI4KIIIβ–expressing KMLC model and determine whether PI4KIIIβ enhances KMLC metastatic propensity and confers vulnerability to PI4KIIIβ antagonists. Our findings will elucidate the way in which PI4KIIIβ drives KMLC progression and may provide a foundation for new therapeutic approaches using PI4KIIIβ antagonists. We show that high PI4KIIIβ levels in 1q–amplified KMLC cells enhanced anterograde vesicular trafficking and stimulated the secretion of pro-survival and pro-metastatic factors. PI4KIIIβ–driven metastatic properties required Golgi phosphoprotein 3 (GOLPH3), a PI4P–tethered Golgi protein that promotes vesicle budding from the trans-Golgi network. Therefore, we postulate that PI4KIIIβ-dependent secretion is required to activate pro- metastatic processes in the tumor microenvironment and maintain the viability of 1q-amplified KMLC cells. To test this hypothesis, we will inactivate Golph3 in PI4KIIIβ-expressing autochthonous KMLCs and 1q-amplified orthotopic KMLCs. Resultant changes in tumor cell viability and inflammatory, stromal, and vascular cell functions in the tumor microenvironment will be measured. We will identify PI4KIIIβ-dependent secreted proteins that mediate these changes and elucidate how they exert these functions. Our findings will provide insight into how a secretory process activated by a chromosomal region that is frequently amplified in cancer maintains tumor cell viability and influences diverse processes in the tumor microenvironment. In summary, the evidence presented here links malignant secretion to a chromosomal region that is frequently amplified in KMLC and provides a basis for clinical studies to develop PI4KIIIβ antagonists as first- in-class inhibitors of malignant secretion. Our findings elucidate the molecular underpinnings of malignant secretion and show that chromosome 1q-amplified cancers are vulnerable to secretory blockade.

很少有有效的治疗方法可用于kras突变肺癌